Real-World Data for Lenvatinib in Radioiodine-Refractory Differentiated Thyroid Cancer (RELEVANT): A Retrospective Multicentric Analysis of Clinical Practice in Austria

Table 4

Real-life studies from Europe and Japan.

Country	N	Age (median; years)	Gender (m/f)	Lenvatinib dose median (min–max)	Median duration of lenvatinib therapy (months)	PFS (median; months)	OS (median; months)	Observation period (median; months)
Italy [22]	94	60	50/46	19.2 mg (10–24 mg)	5.9	10.8	23.8	n.m.
France [23]	75	65	42/33	20 mg (n.m.-24 mg)	6	10	Not reached	7
Austria	43	73	25/18	14 mg (4–24 mg)	27.6	Not reached	Not reached	34.6
Japan [24]	42	66	12/30	Mean 10 mg (4–24 mg)	14.9	n.m.	n.m.	15.4
Netherlands [25]	39	72	20/19	18.6 mg (10–24 mg)	6.1	9.7	18.3	n.m.
Switzerland [26]	13	72	n. m.	n. m. (10–24 mg)	9.98	7.2 (estimated)	22.7 (estimated)	n.m.

n.m. = not mentioned.